CIRS
Chronic Inflammatory Response Syndrome

CIRS is a medical condition defined by Dr. Ritchie Shoemaker as an acute and chronic, systemic inflammatory response acquired following exposure to the interior environment of a water-damaged building with resident toxigenic organisms. This includes bacteria, fungi, actinomycetes, and their associated inflammagens.

Unlike typical allergic reactions to mould, CIRS involves a malfunctioning immune response where the body cannot properly identify and eliminate biotoxins. These toxins circulate continuously in the bloodstream, triggering persistent inflammation across multiple organ systems including the nervous, respiratory, musculoskeletal, and immune systems.

The condition is not rare. Research suggests that approximately 24% of the population carries the HLA-DR genetic haplotype that makes them unable to produce appropriate antibody responses to biotoxins. For these individuals, even limited exposure to water-damaged environments can trigger a cascade of inflammatory reactions.

When buildings sustain water damage from leaks, flooding, or chronic condensation, the moist environment allows rapid growth of toxigenic organisms. These include species such as Stachybotrys chartarum (black mould), Aspergillus, Penicillium, and Chaetomium, all of which produce mycotoxins as part of their metabolic processes.

Mycotoxins are small molecular weight compounds that can become airborne on spore fragments and are easily inhaled. In genetically susceptible individuals, these biotoxins are not properly tagged by antibodies, meaning they evade the normal immune clearance mechanisms and remain circulating in the body.

Beyond fungal mycotoxins, water-damaged buildings also harbour actinomycetes, endotoxins from gram-negative bacteria, beta glucans, mannans, proteinases, and volatile organic compounds. This complex mixture of inflammagens creates what researchers call a toxic soup that is far more harmful than any single mould species alone.

• Mycotoxins from toxigenic mould species like Stachybotrys and Aspergillus
• Endotoxins produced by gram-negative bacteria in damp environments
• Beta glucans and mannans from fungal cell walls
• Microbial volatile organic compounds (MVOCs) released during fungal metabolism
• Proteinases and hemolysins that damage tissue directly

CIRS presents with a cluster of symptoms affecting multiple body systems simultaneously. The condition typically involves at least eight of the following thirteen symptom categories, creating a distinctive clinical picture that distinguishes it from other illnesses.

Neurological symptoms are particularly prominent and include memory difficulties, difficulty with concentration, confusion, disorientation, and word-finding problems. Many patients report feeling as though they are experiencing brain fog that makes routine cognitive tasks challenging.

Physical symptoms span the entire body. Fatigue is almost universal and often debilitating. Joint pain without arthritis, muscle aches, unusual tingling sensations, numbness, ice pick pains, and light sensitivity are frequently reported. Respiratory symptoms include chronic cough, shortness of breath, and sinus congestion that fails to respond to standard treatments.

• Fatigue, weakness, and post-exertional malaise
• Memory problems, brain fog, and difficulty concentrating
• Joint pain, morning stiffness, and muscle aches
• Numbness, tingling, and unusual nerve sensations
• Shortness of breath, chronic cough, and sinus issues
• Abdominal pain, diarrhoea, and digestive disturbances
• Temperature regulation problems and excessive thirst
• Mood changes including anxiety, depression, and irritability

The key to understanding why some people develop CIRS while others remain unaffected lies in genetics. The human leukocyte antigen (HLA) system controls immune response, and specific HLA-DR gene patterns determine whether an individual can mount an appropriate antibody response to biotoxins.

Approximately 24% of the population has HLA-DR types that make them biotoxin-susceptible. Another 2% are considered multisusceptible, meaning they struggle to clear multiple types of biotoxins including those from Lyme disease and ciguatera fish poisoning. These individuals experience the most severe and treatment-resistant forms of CIRS.

HLA-DR testing through blood work can identify genetic susceptibility. Common problematic haplotypes include 4-3-53, 11-3-52B, 7-2-53, 17-2-52A, and 14-5-52B. Knowing your genetic status helps explain why exposure that seems minor to others may trigger severe illness in susceptible individuals.

CIRS diagnosis requires a multi-step approach combining clinical history, symptom assessment, and specific laboratory tests. The Shoemaker Protocol, developed through extensive research, provides a structured diagnostic pathway that has been validated in peer-reviewed medical literature.

The Visual Contrast Sensitivity (VCS) test is often the first screening tool. Biotoxin exposure causes inflammation in the optic nerve, and 92% of CIRS patients show abnormal results on this test. While not diagnostic on its own, an abnormal VCS combined with appropriate history and symptoms supports further investigation.

Laboratory testing reveals characteristic patterns including elevated inflammatory markers such as C4a and TGF-beta 1, abnormal matrix metalloproteinase 9 (MMP-9), low melanocyte stimulating hormone (MSH), elevated leptin, and low vasoactive intestinal polypeptide (VIP). Multiple biomarkers must be assessed together as no single test confirms CIRS.

• Comprehensive symptom evaluation using validated questionnaires
• Visual Contrast Sensitivity testing for biotoxin-related neurological inflammation
• HLA-DR genetic testing to confirm susceptibility
• Blood work including C4a, TGF-beta 1, MMP-9, MSH, VEGF, VIP, and leptin
• Confirmation of exposure through environmental testing or credible history

Treating CIRS requires addressing both the environmental source and the physiological dysfunction. No treatment can succeed while the patient continues exposure to a water-damaged environment. Complete removal from the contaminated building or thorough professional remediation is the essential first step.

The Shoemaker Protocol follows a sequential treatment pathway. Initial therapy typically involves cholestyramine or other bile acid sequestrants that bind biotoxins in the gastrointestinal tract, preventing their reabsorption. This interrupts the enterohepatic recirculation that keeps toxins circulating in the body.

As treatment progresses, additional interventions address specific biomarker abnormalities. These may include antifungal therapy if fungal colonisation is present, VIP nasal spray to restore this critical regulatory peptide, omega-3 fatty acids to reduce inflammation, and high-dose fish oil or statins to lower TGF-beta 1. Treatment is individualised based on laboratory monitoring.

No amount of medical treatment can produce lasting improvement if the patient continues exposure to the biotoxin source. Professional assessment of the indoor environment is essential to identify all water-damaged materials and contamination sources. This goes beyond visible mould to include hidden growth in wall cavities, ceiling spaces, and HVAC systems.

Effective remediation must address the moisture source, remove all contaminated porous materials, and thoroughly clean non-porous surfaces using HEPA vacuuming and appropriate antimicrobial treatments. Simply treating visible mould with bleach or paint is completely inadequate for CIRS patients.

For Sydney properties, assessment should include inspection of areas prone to moisture accumulation due to the coastal climate. Bathrooms, poorly ventilated rooms, areas around windows with condensation, and any location with a history of water intrusion require thorough evaluation. Post-remediation testing confirms that biotoxin levels have been reduced to safe thresholds.

• Complete moisture source identification and repair
• Removal of all porous water-damaged materials including drywall, insulation, and carpets
• HEPA vacuuming and antimicrobial treatment of all surfaces
• HVAC system cleaning or replacement if contaminated
• Post-remediation environmental testing using ERMI or HERTSMI-2 indices

With proper diagnosis, environmental remediation, and adherence to the treatment protocol, most CIRS patients experience significant improvement. However, recovery is gradual, typically taking six to twelve months or longer for complete restoration of biomarkers and symptom resolution.

Patients with genetic susceptibility remain at risk for recurrence if exposed to water-damaged environments again in the future. Ongoing vigilance about indoor air quality, prompt attention to any water damage or leaks, and regular maintenance of ventilation systems are essential preventive measures.

For property owners, preventing water damage through proper building maintenance, addressing condensation issues, ensuring adequate ventilation, and responding immediately to any leaks or flooding protects not only the building structure but also the health of genetically susceptible occupants.

Nanotise provides comprehensive environmental assessments specifically designed to identify biotoxin sources for CIRS patients. Our forensic mould inspections use advanced detection technology to locate hidden contamination that standard inspections miss. We work closely with treating physicians to ensure the remediation meets the strict standards required for biotoxin-sensitive individuals.

Our TGA-registered treatments go beyond surface cleaning to address the root cause of contamination. We use hospital-grade antimicrobials combined with our proprietary CRX nanotechnology barrier protection that provides long-term prevention against regrowth. For CIRS patients, this level of thoroughness is essential for successful recovery.

With 16 years of experience serving Sydney properties, Nanotise understands the unique challenges of the local climate and building types. We have successfully remediated hundreds of properties for health-sensitive occupants, creating safe indoor environments that support healing and prevent relapse. Contact us on 1800 NANOTISE for a confidential assessment.